10.1007/s00125-009-1323-x Diabetologia Summary Keywords Alzheimers disease, amyloid, cerebral glucose metabolism, glucagon-like peptide-1, liraglutide Citation Gejl M, Gjedde A, Egefjord L, Mller A, Hansen SB, Vang K, Rodell A, Brndgaard H, Gottrup H, Schacht A, Mller N, Brock B and Rungby J (2016) In Alzheimers Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial
However, it suggests that in real-world settings with appropriate lifestyle support, the difference between the medications may be smaller than trial data indicate
Feeding mutant flies the antioxidant, N-acetylcysteine amide (NACA), suppressed the neurodegeneration caused by gain-of-function mutation in ACOX1
indicado para superficies de hasta 35 m 2
Nephrol Dialysis Transplant 2019
Niet iedereen reageert hetzelfde op GLP-1-gebaseerde medicatie